According to a recent LinkedIn post from Radial, the company is using Prism neurofeedback technology from GrayMatters Health as part of its approach to treating PTSD. The post notes that this method aims to help patients regulate brain activity without requiring them to verbally revisit traumatic experiences.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights the introduction of Prism Imagine, a new feature that creates a visual representation of a patient’s mental strategy, accessible on mobile devices. The post cites comments from Radial’s CMO, Dr. Owen Scott Muir, suggesting that this tool may support patient engagement and communication with providers and family.
For investors, the post suggests Radial is positioning itself at the intersection of mental health care and digital neurotechnology by integrating third-party tools into its offering. This alignment with technology-enabled, non-pharmacological interventions could enhance differentiation in a crowded behavioral health market.
If Prism-based treatments prove effective and scalable, Radial could benefit from improved patient outcomes and potential payer interest in evidence-backed, lower-intensity interventions. However, commercial impact will depend on clinical validation, reimbursement pathways, and the company’s ability to translate this capability into recurring, reimbursable services.
The reference to an external press release from GrayMatters Health also indicates Radial’s reliance on ecosystem partnerships rather than wholly proprietary technology. For investors, this suggests both reduced development risk and some dependence on third-party innovation and licensing terms in the company’s long-term business model.